Targretin oral (bexarotene oral) / ReXceptor |
2014-003145-99: A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis. |
|
|
| Ongoing | 2 | 50 | Europe | Bexarotene, Capsule, hard, Targretin | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | Relapsing-remitting multiple sclerosis already on interferon-beta therapy, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Not yet recruiting | 1 | 20 | | | Nuclear Medicine and Centre for PET Research Fund, Nuclear Medicine and Centre for Positron Emission Tomography (PET ) Research Fund | Alzheimer's Disease | | | | |
NCT00206479: U19 Project 1 (Targretin Effect on Breast Cancer) |
|
|
| Active, not recruiting | 1 | 30 | US | Targretin, tagretin | Baylor Breast Care Center, National Institutes of Health (NIH) | Breast Cancer | 01/12 | 01/12 | | |
NCT05296304: A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides |
|
|
| Recruiting | 1 | 20 | US | Bexarotene, Targretin®, Total Skin Electron Beam (TSEB) | Memorial Sloan Kettering Cancer Center | Cutaneous T-cell Lymphoma | 03/25 | 03/25 | | |
NCT04664829: The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC |
|
|
| Recruiting | 1 | 12 | RoW | Bexarotene, Targretin, Capecitabine, Xeloda | National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore | Metastatic Triple-Negative Breast Carcinoma | 09/24 | 09/25 | | |